Moreover, Surmeli et al. revealed that the co-treatment ZOL and serine/threonine phosphatase inhibitors was able to potentiate cytotoxicity and apoptosis in human breast cancer cells, inhibiting the PI3K/Akt pathway [109]. This evidence concerns the gene AKT1 and breast carcinoma.